Abbisko Cayman Limited (HK:2256) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, is set to present promising phase 2 study results of its drug pimicotinib at the upcoming American Society of Hematology Annual Conference. The study focuses on pimicotinib’s potential in treating chronic graft-versus-host disease in patients unresponsive to previous treatments. Investors are advised to stay informed as the company explores new therapeutic avenues.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.